EX-99


        BestNet Communications Announces Oncosphere Development Agreement

GRAND RAPIDS, Mich.--(PR Newswire) -- October 25, 2006 - BestNet Communications
Corp. (OTCBB: BESC - News) announced today that Oncologix Corporation, its
wholly owned subsidiary, has entered into an agreement with the Institut fur
Umwelttechnologien GmbH (IUT) of Berlin Germany whereunder IUT will provide
development and testing services in connection with the accomplishment of the
Development Feasibility Phase of the Oncosphere program. The purpose of this
phase is to demonstrate the commercial feasibility of the manufacture of the
Oncosphere. The Oncosphere is the Company's radioactive microsphere product for
the treatment of liver cancer. This phase is the first of several development
stages which, if successful, will result in FDA approval of the Oncosphere for
patient treatment.

Andrew Green, Chairman and CEO of Oncologix, stated, "I am confident that the
demonstrated expertise of IUT combined with the knowledge of medical device
development within Oncologix will result in a successful collaboration. This
agreement will position Oncologix to complete the initial development phase and
prepare for the future production of testing and clinical doses."

While this contract is only for the Development Phase for the next nine months,
discussions with IUT have resulted in an expectation that this may be the
beginning of a long term collaborative effort between the two companies in the
development and testing of the Oncosphere product. IUT will provide facilities,
radiation handling licenses, and personnel with experience in chemistry
(inorganic, organic, and radioisotope), and proven expertise in radiation
protection, dosimetry, and radio-labeling of organic compounds. Activities at
IUT have already begun and include successful low-activity (radiation) labeling
of microspheres. If successful in the Development phase, further collaborations
would be possible for the future phases.

IUT, which was founded in 1992 under the direction of Professor Dr. Jurgen
Leonhardt, has established its expertise in radiation labeling of compounds for
biotechnologies, analytical analysis of radioactive compounds, organic and
inorganic chemistry, radiation and chemical recycling, and homeland security
technologies (transportation, building, and military applications worldwide).
IUT contracts with government and industry partners worldwide to develop new
technologies based on chemical and radioactive components.

Mr. Green added that "as a further example of the global nature of our business
plans, Dr. Andrew S. Kennedy, our Chief Science and Medical Officer, is meeting
with leading physicians in China with Fountain Pharmaceuticals, our licensee for
Oncosphere development and sales in China, Hong Kong and Taiwan. These meetings
are expected to introduce the success of microsphere brachytherapy to Chinese
opinion leaders and assist Fountain's clinical introduction of the Oncosphere
product in China and its development activities.

In his own statement, Dr. Kennedy said, "It is a privilege to share my
experiences with microspheres and liver cancer treatments with my colleagues in
China. Given the large incidence of primary and secondary liver cancer in China,
I believe that radiation microsphere therapy, in particular the Oncosphere
product, will provide significant improvements in care for patients and an
attractive market opportunity for Fountain Pharmaceuticals and Oncologix."




About Best Net Communications Corp. and Oncologix Corp.:
--------------------------------------------------------
BestNet Communications is a global solutions provider of long distance;
conference calling, ClicktoPhone and custom application-based communication
services. BestNet's services are accessed worldwide via the Internet, standard
phones and wireless devices and are delivered using standard phone lines and
equipment. This results in a cost effective high quality service for both
businesses and consumers.

Under the brand name Bestnetcall(TM) (http://WWW.BESTNETCALL.COM) the services
offer subscribers premium quality calls and conference calling, at significantly
lower rates. Calls and conference calls can also be launched via a desktop
application or handheld devices including Palm(TM), Pocket PC(R) and
Blackberry(TM) and used with any standard or wireless phone. In addition the
company's new ClicktoPhone(TM) service (http://WWW.CLICKTOPHONE.COM) enables
clients to add secure and anonymous voice communication connectivity anywhere in
the world to web sites, web banners, pictures, electronic documents, and
customized e-mail calling buttons.

    Contact BestNet at:  investors@bestnetcom.com
                         ------------------------

Oncologix Corporation, based in Atlanta GA, is a wholly owned subsidiary of
BestNet Communications. Oncologix, which is in the start-up phase, develops
advanced medical treatments for soft tissue cancers.

This release contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, which are intended to be
covered by the "safe harbor" created thereby. These statements include the plans
and objectives of management for future operations, including plans and
objectives. The forward-looking statements herein are based on current
expectations that involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are
beyond control of the company. Although the company believes that the
assumptions underlying the forward-looking statements are reasonable, any one of
the assumptions could be inaccurate and, therefore, can be no assurance that the
forward-looking statements included in this release will prove to be accurate.